MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy

A. Tóth, H. Nagy, S. Funk, A. Takáts (Budapest, Hungary)

Meeting: 2016 International Congress

Abstract Number: 1962

Keywords: Dopamine dysregulation syndrome, Levodopa(L-dopa), Psychosis

Session Information

Date: Thursday, June 23, 2016

Session Title: Parkinson's disease: Clinical trials, pharmacology and treatment

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: Here we report the case of a 49-year-old man with a 19 years history of PD presenting DDS while he was on LCIG therapy.

Background: Dopaminergic replacement therapy (DRT) often overactivates the dopaminergic circuits involved in reward-orientated and novelty-seeking behavior, leading to development of impulsive – compulsive disorders. The pathological overuse of Parkinson’s disease (PD) medication (DDS) has been linked to the assumption of levodopa and apomorphine.

Methods: The patient has been on levodopa therapy more than 17 years. He developed severe motor fluctuations since 2003 and DDS since 2008. His daily levodopa dose varied between 2500 – 3000 mg in a random way. No other antiParkinsonian drug was taken.We had difficulties with peroral treatment, so we tested him for LCIG therapy in 2013 – with success. After conversion to LCIG infusion the levodopa dose could be reduced /2000 mg / casette/day/ and the symptoms of DDS gradually disappeared. His motor performance was stable without motor and non-motor fluctuations. Two years after initiation of LCIG treatment he began to overuse the levodopa gel, he consumed even 2 casettes daily, finally the casettes were empty until noon (from 6.00 a.m.). Being short of levodopa gel he took about 2000 mg oral levodopa daily in addition. He had to be admitted to a psychiatric department because of severe disturbing dyskinesias and psychiatric problems: anxiety, hallucinations, desorientation, decreased insight. Combined pharmaceutical and cognitive behavioral therapy /CBT/ has been introduced over 8 weeks with hospitalization, and further 8 following weeks in outpatient care. The LCIG therapy was maintained, the peroral medication was gradually withdrawn. Finally the patient got one casette of LCIG /2000 mg levodopa/ and no other antiParkinsonian drug was given.

Results: The symptoms of DDS were eliminated by the end of the fourth week. The continuous CBT and care resulted a stable mental and physical condition.

Conclusions: LCIG therapy should be taken into account even when considering the treatment possibilities of DDS. A successful outcome may be reached without interrupting the LCIG infusion therapy.

To cite this abstract in AMA style:

A. Tóth, H. Nagy, S. Funk, A. Takáts. Dopamine dysregulation syndrome /DDS/ in LCIG infusion: Successful treatment without interrupting the pump therapy [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/dopamine-dysregulation-syndrome-dds-in-lcig-infusion-successful-treatment-without-interrupting-the-pump-therapy/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dopamine-dysregulation-syndrome-dds-in-lcig-infusion-successful-treatment-without-interrupting-the-pump-therapy/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley